Zolbetuximab, Durvalumab, and FLOT Combination Neoadjuvant Chemotherapy for CLDN18.2-Positive Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Claudin 18.2 (CLDN18.2) is a molecular target expressed in a subset of gastric and gastroesophageal junction (GEJ) adenocarcinomas. Zolbetuximab, a chimeric monoclonal antibody targeting CLDN18.2, has shown clinical benefit in combination with chemotherapy for CLDN18.2-positive unresectable advanced or recurrent gastric cancer, and in Japan, FLOT plus durvalumab is expected to become a standard perioperative treatment for locally advanced gastric/GEJ adenocarcinoma. This trial evaluates whether adding zolbetuximab to FLOT plus durvalumab further improves the pathological response of neoadjuvan

Trial Details

NCT ID
NCT07872722
Phase
PHASE2
Sponsor
National Cancer Center, Japan
Status
RECRUITING
Cancer Type
Gastroesophageal Junction (GEJ) Gastric Cancer
Interventions
  • Zolbetuximab
  • Durvalumab
  • FLOT (5-fluorouracil, leucovorin, oxaliplatin, and docetaxel)
Locations (sample)
  • Saitama, Japan|35.90807,139.65657
  • Tokyo, Japan|35.6895,139.69171
  • Tokyo, Japan|35.6895,139.69171
  • Yokohama, Japan|35.43333,139.65

Key Eligibility Criteria

  • Histologically confirmed gastric cancer (either a general histological type or a lymphoid stroma-type carcinoma) on endoscopic biopsy from the prim…
  • No prior chemotherapy, radiotherapy, or immunotherapy, including treatment for other cancers, and classified as cT2-4 and/or cN+ M0 according to th…
  • Moderate or greater membranous staining in \>-75% of tumor cells confirmed by CLDN18.2 immunohistochemistry.
  • No distant metastasis on contrast-enhanced CT of the chest, upper abdomen, and pelvis.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastroesophageal Junction (GEJ) Gastric Cancer Trials on Trialify →